论文部分内容阅读
目的:探讨血小板衍生生长因子 (PDGF)、癌胚抗原 (CEA) 和糖蛋白抗原 15-3(CA15-3) 联合检测在乳腺癌诊断治疗中的意义。方法 :收集 160 例乳腺癌患者和 150 例体检健康者静脉血本,用 ELISA 法检测血清 PDGF 含量,用放射免疫法检测 CEA 和CA15-3 含量。结果 :乳腺癌组 PDGF 含量为 (600.12±89.57) pg/ml、CEA 含量为 (12.53±2.41) ng/ml 和 CA15-3 含(19.6±3.85) mg/L,均高于健康对照组 [ 分别为 (189.11±100.29) ng/ml、(2.79±0.51) ng/mL 和 (3.1±0.9) mg/l] ,差异有统计学意义 (P<0.01)。血清 PDGF、CEA 和CA15-3 联合检测的敏感性、特异性和诊断阳性率分别为 79.5%、59.6% 和 70.9%。结论:血清 PDGF、CEA 和 CA15-3 联合检测可提高乳腺癌诊断的敏感性和诊断符合率,为乳腺癌患者术前临床诊治和术后辅助治疗提供帮助。
Objective: To investigate the significance of combined detection of platelet derived growth factor (PDGF), carcinoembryonic antigen (CEA) and glycoprotein antigen 15-3 (CA15-3) in the diagnosis and treatment of breast cancer. Methods: 160 patients with breast cancer and 150 healthy controls were enrolled in this study. Serum PDGF levels were measured by ELISA and CEA and CA15-3 by radioimmunoassay. Results: The levels of PDGF in breast cancer group were (600.12 ± 89.57) pg / ml, CEA content was (12.53 ± 2.41) ng / ml and CA15-3 (19.6 ± 3.85) mg / L, (189.11 ± 100.29) ng / ml, (2.79 ± 0.51) ng / mL and (3.1 ± 0.9) mg / l respectively), with significant difference (P <0.01). The sensitivity, specificity and diagnostic positive rates of serum PDGF, CEA and CA15-3 were 79.5%, 59.6% and 70.9% respectively. Conclusion: The combined detection of serum PDGF, CEA and CA15-3 can improve the diagnostic sensitivity and diagnostic coincidence rate of breast cancer, and provide help for the preoperative clinical diagnosis and postoperative adjuvant therapy for breast cancer patients.